Lotus Pharmaceuticals, Inc. (LTUS) is a publicly traded company in the Unknown sector. Across all available filings, 4 corporate insiders have executed 7 transactions totaling $404.3K, demonstrating a bearish sentiment with -$404.3K in net insider flow. The most recent transaction on Jan 24, 2011 involved a transaction of 498,646 shares valued at $0.
No significant insider buying has been recorded for LTUS in the recent period.
No significant insider selling has been recorded for LTUS in the recent period.
Based on recent SEC filings, insider sentiment for LTUS is bearish with an Insider Alignment Score of 0/100 and a net flow of -$404.3K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Lotus Pharmaceuticals, Inc. (LTUS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 4 insiders are actively trading LTUS stock, having executed 7 transactions in the past 90 days. The most active insider is Technology Group Inc Genesis (Executive), who has made 2 transactions totaling $374.0K.
Get notified when executives and directors at LTUS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 24, 2011 | Liu Zhongyi | Executive | Award | 498,646 | $N/A | $0 | |
| Jan 2, 2008 | Rothberg Melvin | Executive | Sale | 30,000 | $1.01 | $30.3K | |
| Aug 21, 2007 | C. Wasserman Adam | Executive | Other | 50,000 | $0.55 | $27.5K | |
| Aug 6, 2007 | Group Inc Genesis Technology | Executive | Sale | 680,000 | $0.55 | $374.0K | |
| Jul 31, 2007 | Group Inc Genesis Technology | Executive | Other | 657,690 | $N/A | $0 | |
| May 31, 2007 | C. Wasserman Adam | Executive | Other | 44,200 | $1.00 | $44.2K | |
| Dec 8, 2006 | Rothberg Melvin | Executive | Other | 30,000 | $1.00 | $30.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 2 | $404.3K | 79.9% |
Other(J) | 4 | $101.7K | 20.1% |
Award(A) | 1 | $0 | 0.0% |
Insider selling pressure at Lotus Pharmaceuticals, Inc. has increased, with 4 insiders executing 7 transactions across all time. Total sales of $404.3K significantly outpace purchases of $0, resulting in a net outflow of $404.3K. This selling activity appears largely discretionary, which may warrant closer attention from investors.